PPARA and Hepatic steatosis: The tumor-suppressive effect of saroglitazar on the development of NASH-induced liver tumorigenesis was most likely associated with the alteration in metabolic programming due to PPAR activation leading to improvement in hepatic steatosis (Fig. 2), attenuation of inflammation, and oxidative stress (Table 1).